BlackRock, Inc. 13D and 13G filings for Recursion Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-05 5:28 pm Purchase | 2024-12-31 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BlackRock Inc. BLK | 23,436,636 6.100% | 2,693,839 (+12.99%) | Filing |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BlackRock Inc. BLK | 20,742,797 7.500% | 0 (Unchanged) | Filing |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BlackRock Inc. BLK | 20,742,797 7.500% | 8,348,925 (+67.36%) | Filing |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BlackRock Inc. BLK | 12,393,872 6.000% | 1,726,248 (+16.18%) | Filing |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BlackRock Inc. BLK | 10,667,624 5.900% | 10,667,624 (New Position) | Filing |